Lord, Abbett & Co
BBNX

Lord, Abbett & Co’s Beta Bionics BBNX Stock Holding History

Lord, Abbett & Co’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-430,403
Closed -$13.1M – 637
2025
Q4 		$13.1M Buy
430,403
+65,955
+18% +$1.76M 0.04% 338
2025
Q3 		$7.24M Sell
364,448
-54,950
-13% -$966K 0.02% 420
2025
Q2 		$6.11M Buy
419,398
+191,238
+84% +$2.71M 0.02% 439
2025
Q1 		$2.79M Buy
+228,160
New +$4.25M 0.01% 499

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Lord, Abbett & Co's BBNX Position: Q1 2026 in Review

Lord, Abbett & Co sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 430,403 shares — an estimated $13.1M sold.

Lord, Abbett & Co first reported a position in BBNX in Q1 2025 and held it in 4 quarters. The position peaked at $13.1M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Lord, Abbett & Co reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
  • Lord, Abbett & Co sold 430,403 Beta Bionics shares in Q1 2026, an estimated $13.1M.
  • Lord, Abbett & Co first reported a position in Beta Bionics in Q1 2025 and held it in 4 quarters.
  • Lord, Abbett & Co's Beta Bionics position peaked at $13.1M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.